Clincosm LogoSign in Get a demo

ZYN: Switching to Potential Reduced Exposure Products in Adult Smokers

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04250727
Collaborator
(none)
30
Enrollment
1
Location
2
Arms
17
Anticipated Duration (Months)
1.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aims to assess the feasibility, acceptability, and the potential harm reduction of switching to potentially lower risk, oral nicotine pouches in adult smokers. Part One of this study aims to assess the interest of current smokers in switching to an e-cigarette device (i.e. JUUL) compared to alternative non-combustible tobacco products (i.e. smokeless tobacco/snus) and/or medicinal nicotine via survey. Part Two will consist of a pilot study of 30 non-treatment seeking adult smokers to investigate within-person changes in smoking behavior as a result of switching to different concentrations of oral nicotine pouch products (i.e. ZYN, 3mg and 6mg nicotine concentration). Additionally, by measuring bio-markers of tobacco exposure from baseline, this will allow the study to assess the potential for harm reduction in switching from cigarettes to oral nicotine pouches.

Condition or Disease Intervention/Treatment Phase
  • Device: ZYN
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
30 current non-treatment seeking adult smokers will be randomized to either the 3mg or 6mg nicotine concentration ZYN condition.30 current non-treatment seeking adult smokers will be randomized to either the 3mg or 6mg nicotine concentration ZYN condition.
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Switching to a Non-tobacco-based Oral Nicotine Product Among Adult Cigarette Smokers: Exploring the Roles of Product Characteristics and User History
Actual Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3mg Nicotine Concentration

15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.

Device: ZYN
30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
Experimental: 6mg Nicotine Concentration

15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.

Device: ZYN
30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.

Outcome Measures

Primary Outcome Measures

  1. Number of participants who switched from cigarettes to the ZYN Pouches. [This will be evaluated at week 4.]

    We will investigate whether switching behavior varies by the 3mg and 6mg nicotine concentrations

  2. Change in levels of biomarkers (nicotine, NNAL, CO) among smokers [Change from baseline to week 4 will be assessed.]

    Participants will provide repeated lab samples for biomarker assessments. Urine and breath carbon monoxide samples will be obtained at baseline, week 4, and week 8 (only if complete switching is reported).

Secondary Outcome Measures

  1. Modified Cigarette Evaluation Scale [These assessments will occur at week 4.]

    To evaluate the acceptability of switching, participants will rate ZYN and how it compares to their preferred cigarettes. Additionally, participants will also be asked how likely it is that they will continue to use ZYN compared to cigarettes. We will utilize items modified from the Modified Cigarette Evaluation Scale adapted for these subjective measures. To evaluate the feasibility of switching to ZYN, we will document how many participants switch entirely to ZYN.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 77 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. 21-77 years old(in line with NIH guidelines for 18+ being the age of consent in adults) (2008 PHS Guideline Update Panel)

  2. English literate

  3. Smoke at least 1 cigarette per day

  4. Expired breath carbon monoxide level ≥ 6ppm at baseline

  5. Not currently actively pursuing smoking cessation services or planning to use evidence-based cessation tools to quit in the next month

  6. Not interested in the use of existing FDA-approved tobacco pharmacotherapies (i.e., NRT, wellbutrin, varenicline).

Exclusion Criteria:

  1. Currently using any stop smoking treatments (2008 PHS Guideline Update Panel)

  2. History of serious psychiatric condition (i.e., bipolar disorder, schizophrenia)

  3. Current uncontrolled medical condition

  4. Cardiac conditions that required a hospitalization or intensive treatment on an outpatient basis in the past year including: myocardial infarction, coronary artery disease, unstable angina, congestive heart failure, or tachyarrhythmias (including rapid atrial fibrillation, ventricular tachycardia, or ventricular fibrillation)

  5. Female participants of child-bearing age will be excluded if they are currently pregnant or breastfeeding or report an unwillingness to use effective birth control (i.e., abstinence, IUD, implant, sterilization, pill, patch, ring, or barrier method such as condoms) for the duration of the study

  6. Severe lung disease that requires supplemental oxygen

  7. Uncontrolled asthma (<20 on the Asthma Control Test (ACT) or requiring steroids more than 1x per year)

  8. Unstable COPD: defined as GOLD category C or D (more than 2 exacerbations or 1 exacerbation leading to hospitalization in the past year)

  9. Planning to quit smoking with a set goal or time for quit attempt

  10. Known hypersensitivity to propylene glycol

  11. Patients with an FEV1 < 40%

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale University New Haven Connecticut United States 06520

Sponsors and Collaborators

  • Yale University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT04250727
Other Study ID Numbers:
  • 2000023826
First Posted:
Jan 31, 2020
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:
Carcinogenesis
Tobacco Use Disorder

Study Results

No Results Posted as of Jun 21, 2022